For example, the central nervous system (CNS) tumor samples had low frequencies of four different biomarkers approved in all solid tumor indications (5.4% collectively across BRAF V600E, NTRK2 fusion, TMB-high, and MSI-high), whereas the frequency of biomarkers associated with off-label FDA-approved matched therapies was much higher (43.9%). This evidence concerns the gene NTRK2 and neoplasm.